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Exome sequencingAlzheimer's disease is a complex neurodegenerative disorder. A large number of genome-wide association
studies have been performed, which have been supplemented more recently by the ﬁrst epigenome-wide
association studies, leading to the identiﬁcation of a number of novel loci altered in disease. Twin studies have
shown monozygotic twin discordance for Alzheimer's disease (Gatz et al., 2006), leading to the conclusion
that a combination of genetic and epigenetic mechanisms is likely to be involved in disease etiology (Lunnon
& Mill, 2013). This review focuses on identifying overlapping pathways between published genome-wide
association studies and epigenome-wide association studies, highlighting dysfunctional synaptic, lipid
metabolism, plasma membrane/cytoskeleton, mitochondrial, and immune cell activation pathways.
Identifying common pathways altered in genetic and epigenetic studies will aid our understanding of
disease mechanisms and identify potential novel targets for pharmacological intervention.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dementia encompasses a group of chronic neurodegenerative
diseases that affected an estimated 44.4 million people worldwide in
2013. Because of an increasingly aging population, it is predicted that
this ﬁgure will rise to an estimated 75.6 million by 2030 and 135.5
million by 2050 (Prince et al., 2013). The worldwide cost of dementia
was estimated to be $604 billion in 2010 (Wimo & A.s.D. International,
2010). Alzheimer's disease (AD) is the most common form of
dementia, accounting for ~60%–80% of cases worldwide (Lobo et al.,
2000). AD is characterized by the accumulation of extracellular
amyloid-β (Aβ) plaques, intracellular neuroﬁbrillary tangles of
hyperphosporylated tau, and widespread gliosis in the brain
(Serrano-Pozo et al., 2011). Despite the progress that has been
made in understanding the cellular pathology of AD, available
treatments only temporarily alleviate some symptoms and do not
modify the underlying disease process. By the time an individual
becomes symptomatic, there are already considerable neuronal cell
loss, plaque deposition, and tangle burdenwithin the brain, which can
appear up to 10 years before a clinical diagnosis is made (Jack et al.,
2010). Reﬂecting the growing public health and socioeconomic
burden of AD, there has been a year-on-year increase in the numberInc. This is an open access article uof publications investigating the etiology of the disease (Fig. 1) as
researchers seek novel disease-modifying treatments.
Although the neuropathology associated with AD has been well
described, little is known about the mechanisms underlying disease
onset and progression. Quantitative genetic analyses demonstrated
high heritability estimates (58%–79%) for AD (Gatz et al., 2006), and
thus, initial approaches to understanding etiology focused on
uncovering a genetic contribution to disease susceptibility. In recent
years, the recruitment of large cohorts and the relatively inexpensive
cost of assessing genetic variation through genome-wide association
studies (GWAS) have allowed the identiﬁcation of multiple variants
associated with an elevated risk of developing AD. Many of these
genes have also been robustly associated with AD via subsequent
meta-analyses (Harold et al., 2009; Hollingworth et al., 2011; Lambert
et al., 2013a; Naj et al., 2011), and most recently, polygenic risk
scores for AD have been developed (Escott-Price et al., 2015).
Collectively, common single nucleotide polymorphisms (SNPs) are
believed to only account for 33% of attributable risk (Ridge et al.,
2013), and the mechanism behind their action remains largely
unknown. Exome-sequencing projects have also identiﬁed other
variants, for example, TREM2 (Guerreiro et al., 2013), which have a
larger effect size, yet these are relatively rare. In recent years,
researchers have used epigenome-wide association studies (EWAS) to
identify epigenetic changes in disease with the aim to elucidate
additional mechanisms of pathology, which may provide a link to
environmental factors.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. The number of publications in the ﬁeld of AD. Shown is the number of publications within the PubMed database that can be identiﬁed using the search term Alzheimer's disease
between 1969 and 2015.
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expression, occurring independently of DNA sequence variation and
acting principally through chemical modiﬁcations to DNA and
nucleosomal histone proteins. Dynamic changes to the epigenome
orchestrate a diverse range of important neurobiological and
cognitive processes in the brain (Lunnon & Mill, 2013). DNA
methylation is the best characterized and most stable epigenetic
modiﬁcation which modulates the transcription of mammalian
genomes. This is due to its ability to be interrogated using archived
genomic DNA resources, which are the focus of most human
epidemiological epigenetic research to date (Lunnon & Mill, 2013).
The methylation of a cytosine in a CpG dinucleotide by DNA
methyltransferase enzymes forms 5-methylcytosine, which can
disrupt the cell's transcriptional machinery by blocking the binding
of transcription factors and attracting methyl-binding proteins that
initiate chromatin compaction and bring about gene silencing (Klose
& Bird, 2006). The predominant focus to date is methylation within
CpG islands located within the 5′ promoters of many constitutively
expressed housekeeping control genes. However, recent data suggest
that the relationship between DNA methylation and transcription
may be more complex, with gene body methylation and non-CpG
methylation often being associated with active gene expression (Aran
et al., 2011; Ball et al., 2009; Hellman & Chess, 2007; Lister et al., 2009)
and alternative splicing (Flores et al., 2012; Lyko et al., 2010). The
mechanisms involved in cytosine demethylation have also been
studied; its demethylation by ten-eleven translocation (TET) enzymes
leads to a stepwise change in the cytosine side chain state from
methylated cytosine to hydroxymethylated cytosine (5-hmC), to
formyl cytosine, to carboxyl cytosine, and ﬁnally back to unmodiﬁed
cytosine by a yet unclassiﬁed enzyme/mechanism (Hill et al., 2014).
Each of these intermediates may have their own effect on gene
transcription, splicing, and subsequent protein function, and recent
studies have shown 5-hmC to be at high levels in the brain (Nestor et
al., 2012; Song et al., 2011), with variation across different anatomical
regions (Lunnon et al., 2016). Recent advances in genomic technology
have allowed the ﬁrst genome-scale studies assessing methylomic
variation (EWAS) in AD. These studies have identiﬁed AD-associated
DNA methylomic variation at numerous loci in the cortex, with
consistent ﬁndings across multiple independent study cohorts, in
addition to brain-region–speciﬁc changes and blood DNAmethylation
signatures (Lunnon et al., 2014; De Jager et al., 2014). In addition, arecent paper by Yu et al. combined genetic and epigenetic ﬁndings by
examining DNA methylation patterns across genes that have
previously been nominated by GWAS, identifying several overlapping
loci (Yu et al., 2014).
Although GWAS and EWAS analyses have identiﬁed multiple
genes associated with AD, the extent to which common pathways are
shared in the ﬁndings across studies has not yet been explored. This
review aims to integrate the most robust ﬁndings from GWAS, exome
sequencing studies, and EWAS performed to date in AD to highlight
common molecular pathways, which could ultimately aid in the
identiﬁcation of novel pharmacological targets for the disease.
2. Methods
Using the publically available online search GWAS catalogue
(https://www.ebi.ac.uk/gwas/search?query=Alzheimer%27s%
20disease#association) and a P value cutoff of P b 5 × 10−8, we
identiﬁed 45 unique GWAS in AD totaling 144 SNPs.We then removed
studies based on poor sample size (b1000 total samples) as well as
those studies that included samples that were non-European in origin.
Following the study selection, SNPs in intronic regions were removed
from the analysis. After ﬁltering for associated disease outcome
measures, including the terms Dementia and core Alzheimer's disease
neuropathological changes, Alzheimer's disease late onset, Alzheimer's
disease, Psychosis and Alzheimer's disease, Alzheimer's disease age of
onset, Alzheimer's disease biomarkers, and Neuroﬁbrillary tangles, we
were left with 22 studies with 49 SNPs in 32 unique genes (Table 1A)
(Harold et al., 2009; Hollingworth et al., 2011; Lambert et al., 2013a;
Naj et al., 2011; Coon et al., 2007; Webster et al., 2008; Li et al., 2008;
Kamboh et al., 2012a; Kamboh et al., 2012b; Lambert et al., 2009;
Seshadri et al., 2010; Naj et al., 2010; Perez-Palma et al., 2014; Nelson
et al., 2014; Abraham et al., 2008; Antunez et al., 2011; Hollingworth
et al., 2012; Cruchaga et al., 2013; Hu et al., 2011; Lambert et al.,
2013b; Beecham et al., 2014; Jonsson et al., 2013). Four genes were
identiﬁed from exome sequencing studies (Guerreiro et al., 2013;
Guerreiro et al., 2012; Cruchaga et al., 2014; Pottier et al., 2012) by
performing a literature search in PubMed using the phrases
Alzheimer's disease and Exome sequencing alone and in combination
(Table 1B). Genes from EWAS were compiled from the 2014
publications by Lunnon et al. and De Jager et al. including probes
with P b 1 × 10−7 (Lunnon et al., 2014; De Jager et al., 2014). The
Table 1A
Genes nominated from GWAS
Gene SNPs
identiﬁed
P value GO annotation Chromosome Position Title of article First author
and year
Reference
ABCA7 rs3764650 5.00E-17 GO:0,005,215 transporter
activity
GO:0,005,524 ATP binding
GO:0,005,548 phospholipid
transporter activity
GO:0,016,887 contributes
to ATPase activity
19 1,046,521 Common Variants at
ABCA7, MS4A6A/
MS4A4E, EPHA1, CD33
and CD2AP Are
Associated With
Alzheimer's Disease
Hollingworth,
2011
(Hollingworth et al.,
2011)
rs4147929 1.00E-15 19 1,063,444 Meta-Analysis of 74,046
Individuals Identiﬁes 11
New Susceptibility Loci
for Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
APOE, APOC1,
TOMM40
rs4420638 1.00E-39 APOE
GO:0,001,540 beta-
amyloid binding IDA
11305869
GO:0,005,319 lipid
transporter activity IDA
17305370
GO:0,005,515 protein
binding IPI 12950167
GO:0,005,543 phospholipid
binding
19 44,919,689 A High-Density Whole-
Genome Association Study
Reveals That APOE Is the
Major Susceptibility Gene
for Sporadic Late-Onset
Alzheimer's Disease
Coon, 2007 (Coon et al., 2007)
1.00E-39
Sorl1 as an Alzheimer's
Disease Predisposition
Gene?
Webster,
2008
(Webster et al., 2008)
2.00E-44 Candidate Single-
Nucleotide Polymorphisms
From a Genomewide
Association Study of
Alzheimer Disease
Li, 2008 (Li et al., 2008)
1.00E-12 Genome-Wide
Association Analysis of
Age-at-Onset in
Alzheimer's Disease
Kamboh,
2012a
(Kambohet al., 2012a)
8.00E-149 Genome-Wide
Association Study of
Alzheimer's Disease
Kamboh,
2012b
(Kambohetal., 2012b)
rs2075650 2.00E-157 APOC1
GO:0,004,859 phospholipase
inhibitor activity
GO:0,005,504 fatty acid
binding
GO:0,031,210
phosphatidylcholine binding
GO:0,055,102 lipase inhibitor
activity
GO:0,060,228
phosphatidylcholine-sterol
O-acyltransferase activator
activity
19 44,892,362 Genome-Wide
Association Study
Identiﬁes Variants at CLU
and PICALM Associated
With Alzheimer's Disease
Harold, 2009 (Harold et al., 2009)
2.00E-16 Genome-Wide Association
Study Identiﬁes Variants at
CLU and CR1 Associated
With Alzheimer's Disease
Lambert,
2009
(Lambert et al., 2009)
1.00E-295 Genome-Wide Analysis
of Genetic Loci Associated
With Alzheimer Disease
Seshadri,
2010
(Seshadri et al., 2010)
5.00E-36 Dementia Revealed: Novel
Chromosome 6 Locus for
Late-Onset Alzheimer
Disease Provides Genetic
Evidence for Folate-Pathway
Abnormalities
Naj, 2010 (Naj et al., 2010)
9.00E-116 Overrepresentation of
Glutamate Signaling in
Alzheimer's Disease:
Network-Based Pathway
Enrichment Using
Meta-Analysis of
Genome-Wide
Association Studies
Perez-Palma,
2014
(Perez-Palma et al.,
2014)
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Table 1A (continued)
Gene SNPs
identiﬁed
P value GO annotation Chromosome Position Title of article First author
and year
Reference
4.00E-13 TOMM40
GO:0,008,320 protein
transmembrane
transporter activity
GO:0,015,288 porin
activity
ABCC9 Gene Polymorphism
Is AssociatedWith
Hippocampal Sclerosis of
Aging Pathology
Nelson, 2014 (Nelson et al., 2014)
rs6859 6.00E-14 19 44,878,777 A Genome-Wide
Association Study for
Late-Onset Alzheimer's
Disease Using DNA Pooling
Abraham,
2008
(Abrahametal., 2008)
rs157580 8.00E-89 19 44,892,009 The Membrane-Spanning
4-Domains, Subfamily A
(MS4A) Gene Cluster
Contains a Common
Variant Associated With
Alzheimer's Disease
Antunez,
2011
(Antunez et al., 2011)
rs157582 9.00E-52 19 44,892,962 Genome-Wide
Association Study of
Alzheimer's Disease With
Psychotic Symptoms
Hollingworth,
2012
(Hollingworth et al.,
2012)
rs769449 2.00E-18 19 44,906,745 GWAS of Cerebrospinal
Fluid tau Levels Identiﬁes
Risk Variants for
Alzheimer's Disease
Cruchaga,
2013
(Cruchaga et al., 2013)
BIN1 rs7561528 4.00E-14 GO:0,005,515 protein
binding
GO:0,032,403 protein
complex binding
GO:0,042,802 identical
protein binding
GO:0,046,982 protein
heterodimerization activity
GO:0,048,156 tau protein
binding
2 127,132,061 Common Variants at
MS4A4/MS4A6E, CD2AP,
CD33 and EPHA1 Are
AssociatedWith Late-Onset
Alzheimer's Disease
Naj, 2011 (Naj et al., 2011)
6.00E-11 Genome-Wide
Association Study of
Alzheimer's Disease
Kamboh,
2012b
(Kambohetal., 2012b)
rs744373 3.00E-14 2 127,137,039 Common Variants at
ABCA7, MS4A6A/
MS4A4E, EPHA1, CD33
and CD2AP Are
Associated With
Alzheimer's Disease
Hollingworth,
2011
(Hollingworth et al.,
2011)
1.00E-10 Meta-Analysis for
Genome-Wide
Association Study
Identiﬁes Multiple
Variants at the BIN1 Locus
Associated With
Late-Onset Alzheimer's
Disease
Hu, 2011 (Hu et al., 2011)
2.00E-09 The Membrane-Spanning
4-Domains, Subfamily A
(MS4A) Gene Cluster
Contains a Common
Variant Associated With
Alzheimer's Disease
Antunez,
2011
(Antunez et al., 2011)
rs6733839 7.00E-44 2 127,135,234 Meta-Analysis of 74,046
Individuals Identiﬁes 11
New Susceptibility Loci
for Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
rs12989701 3.00E-10 2 127,130,409 Meta-Analysis for
Genome-Wide Association
Study Identiﬁes Multiple
Variants at the BIN1 Locus
AssociatedWith Late-Onset
Alzheimer's Disease
Hu, 2011 (Hu et al., 2011)
CASS4 rs7274581 3.00E-08 GO:0,000,155
phosphorelay sensor
kinase activity
GO:0,005,515 protein
binding
20 56,443,204 Meta-Analysis of 74,046
Individuals Identiﬁes 11
New Susceptibility Loci
for Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
CD2AP rs10948363 5.00E-11 GO:0,005,200 structural
constituent of cytoskeleton
GO:0,005,515 protein binding
6 47,520,026 Meta-Analysis of 74,046
Individuals Identiﬁes 11
New Susceptibility Loci
Lambert,
2013a
(Lambert et al., 2013a)
(continued on next page)
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Table 1A (continued)
Gene SNPs
identiﬁed
P value GO annotation Chromosome Position Title of article First author
and year
Reference
GO:0,017,124 SH3 domain
binding
for Alzheimer's Disease
rs9349407 9.00E-09 6 47,485,642 Common Variants at
MS4A4/MS4A6E, CD2AP,
CD33 and EPHA1 Are
AssociatedWith Late-Onset
Alzheimer's Disease
Naj, 2011 (Naj et al., 2011)
CD33 rs3865444 2.00E-09 GO:0,004,872 receptor
activity
GO:0,005,515 protein binding
GO:0,030,246 carbohydrate
binding
19 51,224,706 Common Variants at
MS4A4/MS4A6E, CD2AP,
CD33 and EPHA1 Are
AssociatedWith Late-Onset
Alzheimer's Disease
Naj, 2011 (Naj et al., 2011)
CELF1 rs10838725 1.00E-08 GO:0,000,166 nucleotide
binding
GO:0,000,900 translation
repressor activity, nucleic
acid binding
GO:0,003,723 RNA binding
IDA 16946708
GO:0,003,729 mRNA binding
11 47,536,319 Meta-Analysis of 74,046
Individuals Identiﬁes 11
New Susceptibility Loci
for Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
CLU rs9331896 3.00E-25 GO:0,005,515 protein binding
GO:0,016,887 NOT ATPase
activity
GO:0,031,625 ubiquitin
protein ligase binding
GO:0,051,087 chaperone
binding
GO:0,051,787 misfolded
protein binding
8 27,610,169 Meta-Analysis of 74,046
Individuals Identiﬁes 11
New Susceptibility Loci
for Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
rs2279590 6.00E-10 8 27,598,736 Genome-Wide Association
Study Identiﬁes Variants at
CLU and CR1 Associated
With Alzheimer's Disease
Lambert,
2009
(Lambert et al., 2009)
rs11136000 9.00E-10 8 27,607,002 Genome-Wide
Association Study
Identiﬁes Variants at CLU
and PICALM Associated
With Alzheimer's Disease
Harold, 2009 (Harold et al., 2009)
rs569214 4.00E-08 8 27,630,273 The Membrane-Spanning
4-Domains, Subfamily A
(MS4A) Gene Cluster
Contains a Common
Variant Associated With
Alzheimer's Disease
Antunez,
2011
(Antunez et al., 2011)
CR1 rs6656401 6.00E-24 GO:0,001,851 complement
component C3b binding
GO:0,001,855 complement
component C4b binding
GO:0,001,861 complement
component C4b receptor
activity
GO:0,004,877 complement
component C3b receptor
activity
1 207,518,704 Meta-Analysis of 74,046
Individuals Identiﬁes 11
New Susceptibility Loci
for Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
rs3818361 4.00E-14 1 207,611,623 Common Variants at
ABCA7, MS4A6A/
MS4A4E, EPHA1, CD33
and CD2AP Are
Associated With
Alzheimer's Disease
Hollingworth,
2011
(Hollingworth et al.,
2011)
rs6656401 3.00E-10 1 207,518,704 Genome-Wide
Association Study
Identiﬁes Variants at CLU
and CR1 Associated With
Alzheimer's Disease
Lambert,
2009
(Lambert et al., 2009)
rs6701713 5.00E-10 1 207,612,944 Common Variants at
MS4A4/MS4A6E, CD2AP,
CD33 and EPHA1 Are
Associated With
Late-Onset Alzheimer's
Disease
Naj, 2011 (Naj et al., 2011)
FERMT2 rs17125944 8.00E-09 GO:0,005,515 protein
binding
GO:0,005,547
phosphatidylinositol-
14 52,933,911 Meta-Analysis of 74,046
Individuals Identiﬁes 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
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Table 1A (continued)
Gene SNPs
identiﬁed
P value GO annotation Chromosome Position Title of article First author
and year
Reference
3,4,5-trisphosphate
binding
FRMD4A rs7081208 1.00E-10 GO:0,030,674 protein
binding, bridging
10 13,949,865 Genome-Wide Haplotype
Association Study Identiﬁes
the FRMD4A Gene as a Risk
Locus for Alzheimer's
Disease
Lambert,
2013b
(Lambert et al., 2013b)
GLIS3 rs514716 3.00E-09 GO:0,000,978 RNA
polymerase II core
promoter proximal
region sequence-
speciﬁc DNA binding
sequence-speciﬁc DNA
binding transcription
factor activity involved
in positive regulation
of transcription
GO:0,001,078 RNA
polymerase II core
promoter proximal
region sequence-speciﬁc
DNA binding transcription
factor activity involved in
negative regulation of
transcription
9 3,929,424 GWAS of Cerebrospinal
Fluid tau Levels Identiﬁes
Risk Variants for
Alzheimer's Disease
Cruchaga,
2013
(Cruchaga et al., 2013)
HLA-DRB5 rs9271192 3.00E-12 GO:0,042,605 peptide
antigen binding
6 32,610,753 Meta-Analysis of 74,046
Individuals Identiﬁes 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
INPP5D rs35349669 3.00E-08 GO:0,004,445 inositol-
polyphosphate 5-
phosphatase activity
GO:0,005,515 protein
binding
GO:0,017,124 SH3 domain
binding
GO:0,034,594
phosphatidylinositol
trisphosphate phosphatase
activity
GO:0,051,425 PTB
domain binding
2 233,159,830 Meta-Analysis of 74,046
Individuals Identiﬁes 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
MEF2C rs190982 3.00E-08 GO:0,000,977 RNA
polymerase II regulatory
region sequence-speciﬁc
DNA binding
GO:0,000,978 RNA
polymerase II core promoter
proximal region sequence-
speciﬁc DNA binding
GO:0,000,980 RNA
polymerase II distal enhancer
sequence-speciﬁc DNA binding
GO:0,000,981 sequence-
speciﬁc DNA binding RNA
polymerase II transcription
factor activity
GO:0,000,983 RNA polymerase
II core promoter sequence-
speciﬁc DNA binding
transcription factor activity
5 88,927,603 Meta-Analysis of 74,046
Individuals Identiﬁes 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
MS4A4A rs4938933 8.00E-12 GO:0,016,021 integral
component of membrane
11 60,266,956 Common Variants at
MS4A4/MS4A6E, CD2AP,
CD33 and EPHA1 Are
Associated With Late-Onset
Alzheimer's Disease
Naj, 2011 (Naj et al., 2011)
MS4A4E,
MS4A6A
rs610932 2.00E-14 MS4A4E GO:0,016,021
integral component of
membrane
11 60,171,834 Common Variants at
ABCA7, MS4A6A/MS4A4E,
EPHA1, CD33 and CD2AP
Are Associated With
Alzheimer's Disease
Hollingworth,
2011
(Hollingworth et al.,
2011)
rs983392 6.00E-16 MS4A6A GO:0,016,021
integral component of membrane
11 60,156,035 Meta-Analysis of 74,046
Individuals Identiﬁes 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
(continued on next page)
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Table 1A (continued)
Gene SNPs
identiﬁed
P value GO annotation Chromosome Position Title of article First author
and year
Reference
MTHFD1L rs11754661 2.00E-10 GO:0,004,329 formate-
tetrahydrofolate ligase activity
GO:0,004,477 NOT
methenyltetrahydrofolate
cyclohydrolase activity
GO:0,004,488 NOT
methylenetetrahydrofolate
dehydrogenase (NADP+) activity
GO:0,005,524 ATP binding
6 150,885,942 Dementia Revealed: Novel
Chromosome 6 Locus for
Late-Onset Alzheimer
Disease Provides Genetic
Evidence for
Folate-Pathway
Abnormalities
Naj, 2010 (Naj et al., 2010)
NME8 rs2718058 5.00E-09 GO:0,004,550 nucleoside
diphosphate kinase activity IBA
GO:0,005,524 ATP
binding
7 37,801,932 Meta-Analysis of 74,046
Individuals Identiﬁes 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
PICALM rs10792832 9.00E-26 GO:0,005,515 protein
binding
GO:0,005,545
1-phosphatidylinositol
binding
GO:0,030,276 clathrin
binding
GO:0,032,050 clathrin
heavy chain binding
11 86,156,833 Meta-Analysis of 74,046
Individuals Identiﬁes 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
rs561655 7.00E-11 11 86,089,237 Common Variants at
MS4A4/MS4A6E, CD2AP,
CD33 and EPHA1 Are
Associated With Late-Onset
Alzheimer's Disease
Naj, 2011 (Naj et al., 2011)
rs3851179 1.00E-09 11 86,157,598 Genome-Wide Association
Study Identiﬁes Variants at
CLU and PICALM Associated
With Alzheimer's Disease
Harold, 2009 (Harold et al., 2009)
rs536841 3.00E-09 11 86,076,782 The Membrane-Spanning
4-Domains, Subfamily A
(MS4A) Gene Cluster
Contains a Common Variant
Associated With
Alzheimer's Disease
Antunez,
2011
(Antunez et al., 2011)
rs17817600 2.00E-08 11 85,966,428 Genome-Wide Association
Study of Alzheimer's
Disease
Kamboh,
2012b
(Kambohet al., 2012b)
PTK2B rs28834970 7.00E-14 GO:0,004,683 calmodulin-
dependent protein kinase
activity
GO:0,004,713 protein
tyrosine kinase activity
GO:0,004,715 non-membrane
spanning protein tyrosine
kinase activity
GO:0,004,871 signal
transducer activity
8 27,337,604 Meta-Analysis of 74,046
Individuals Identiﬁes 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
PVRL2 rs6857 2.00E-62 GO:0,001,618 virus receptor
activity
GO:0,005,515 protein binding
GO:0,015,026 coreceptor activity
GO:0,042,802 identical protein
binding
GO:0,042,803 protein
homodimerization activity
19 44,888,997 Genome-Wide Association
Meta-analysis of
Neuropathologic Features
of Alzheimer's Disease and
Related Dementias
Beecham,
2014
(Beecham et al., 2014)
SLC24A4,
RIN3
rs10498633 6.00E-09 SLC24A4 GO:0,008,273 calcium,
potassium:sodium antiporter
activity
GO:0,015,293 symporter activity
14 92,460,608 Meta-Analysis of 74,046
Individuals Identiﬁes 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
RIN3 GO:0,005,096 GTPase
activator activity
GO:0,005,515 protein binding
GO:0,017,112 Rab guanyl-
nucleotide exchange factor activity
GO:0,017,137 Rab GTPase binding
SORL1 rs11218343 1.00E-14 GO:0,001,540 beta-amyloid binding
GO:0,004,888 transmembrane
signaling receptor activity
GO:0,005,515 protein binding
GO:0,030,169 low-density
lipoprotein particle binding
11 121,564,878 Meta-Analysis of 74,046
Individuals Identiﬁes 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
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Table 1A (continued)
Gene SNPs
identiﬁed
P value GO annotation Chromosome Position Title of article First author
and year
Reference
GO:0,030,306 ADP-ribosylation
factor binding
NCR2 rs6922617 4.00E-08 GO:0,004,888 transmembrane
signaling receptor activity
6 41,368,363 GWAS of Cerebrospinal
Fluid tau Levels Identiﬁes
Risk Variants for
Alzheimer's Disease
Cruchaga,
2013
(Cruchaga et al., 2013)
TREM2 rs75932628 2.00E-12 GO:0,001,530 lipopolysaccharide
binding
GO:0,004,872 receptor activity
GO:0,005,515 protein binding
GO:0,042,834 peptidoglycan
binding
GO:0,070,891 lipoteichoic
acid binding
6 41,161,514 Variant of TREM2
Associated With the Risk of
Alzheimer's Disease
Jonsson, 2013 (Jonsson et al., 2013)
UTS2D rs9877502 5.00E-09 GO:0,001,664 G-protein coupled
receptor binding
GO:0,005,179 hormone activity
3 190,951,729 GWAS of Cerebrospinal
Fluid tau Levels Identiﬁes
Risk Variants for
Alzheimer's Disease
Cruchaga,
2013
(Cruchaga et al., 2013)
ZCWPW1 rs1476679 6.00E-10 GO:0,008,270 zinc ion binding 7 100,406,823 Meta-Analysis of 74,046
Individuals Identiﬁes 11
New Susceptibility Loci for
Alzheimer's Disease
Lambert,
2013a
(Lambert et al., 2013a)
Shown are the genes identiﬁed from GWAS and their respective SNPs, associated P value, GO annotation, chromosome and genomic position, and the relevant study. Only SNPs with
Pb 5 × 10−8 were included.
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based on sample size (Bakulski et al., 2012). Gene names were
checked against quoted genomic location using the UCSC Genome
Browser; only genes containing a probe of interest were included. The
resulting gene list contained 48 unique genes that met the criteria for
inclusion for our study (Table 2). Gene annotation for all genes of
interest were taken from the Gene Ontology (GO) Consortium
database, where available, and supplemented with information from
the Entrez gene database. Two genes overlapped between GWAS andTable 1B
Genes nominated from exome sequencing studies
Gene SNPs
identiﬁed
GO annotation Chromosome
TREM2 rs2234255 GO:0,001,530 lipopolysaccharide binding
GO:0,004,872 receptor activity
GO:0,005,515 protein binding
GO:0,042,834 peptidoglycan binding
GO:0,070,891 lipoteichoic acid binding
6
rs147564421 6
rs2234253 6
rs142232675 6
rs201258663 6
rs75932628 6
#N/A 6
SORL1 #N/A GO:0,001,540 beta-amyloid binding
GO:0,004,888 transmembrane signaling
receptor activity
GO:0,005,515 protein binding
GO:0,030,169 low-density lipoprotein
particle binding
GO:0,030,306 ADP-ribosylation factor binding
11
#N/A 11
#N/A 11
NOTCH3 rs10408676 GO:0,005,509 calcium ion binding
GO:0,005,515 protein binding
GO:0,019,899 enzyme binding
19
PLD3 rs145999145 GO:0,004,630 phospholipase D activity
GO:0,005,515 protein binding
GO:0,070,290 N-
acylphosphatidylethanolamine-speciﬁc
phospholipase D activity
19
Shown are the genes identiﬁed from exome sequencing studies and their respective SNPs,exome sequencing studies (TREM2, SORL1), and 1 gene overlapped
between GWAS and EWAS (BIN1), bringing the total number of genes
across all analyses to 81.
3. Pathways
The 81 genes identiﬁed were compared in terms of their
molecular/cellular function and grouped by pathways in which the
identiﬁed genes operate. By taking signiﬁcant loci across multiplePosition Title of article First author
and year
Reference
41,127,543 TREM2 Variants in
Alzheimer's Disease
Guerreiro, 2013 (Guerreiro et al., 2013)
41,129,100
41,129,105
41,129,133
41,129,195
41,129,252
41,129,279
1.21E + 08 High Frequency of
Potentially Pathogenic
SORL1 Mutations in
Autosomal Dominant
Early-Onset Alzheimer
Disease
Pottier, 2012 (Pottier et al., 2012)
1.21E + 08
1.21E + 08
15,290,007 Exome Sequencing Reveals
an Unexpected Genetic
Cause of Disease: NOTCH3
Mutation in a Turkish Family
With Alzheimer's disease
Guerreiro, 2012 (Guerreiro et al., 2012)
40,877,595 Rare Coding Variants in the
Phospholipase D3 Gene
Confer Risk for Alzheimer's
Disease
Cruchaga, 2014 (Cruchaga et al., 2014)
GO annotation, chromosome and genomic position, and the relevant study.
Table 2
Genes nominated from EWAS
Gene Probes
identiﬁed
P value Functional summary, GO
annotation
Chromosome Position Title of article First author
and year
Reference
ABR cg25018458 1.89E-10 GO:0,005,089 Rho
guanyl-nucleotide exchange
factor activity
GO:0,005,096 GTPase activator
activity
17 980,014 Methylomic Proﬁling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
ALDH16A1 cg20618448 1.16E-08 GO:0,004,029 aldehyde
dehydrogenase (NAD) activity
19 49,962,324 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
ANK1 cg05066959 7.13E-14 GO:0,005,198 structural molecule
activity
GO:0,005,200 structural
constituent of cytoskeleton
GO:0,005,515 protein binding
GO:0,008,093 cytoskeletal adaptor
activity
GO:0,019,899 enzyme binding
GO:0,030,507 spectrin binding
GO:0,051,117 ATPase binding
8 41,519,308 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
1.24E-09 8 41,519,308 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
[29
cg11823178 7.83E-14 8 41,519,399 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
3.42E-11 8 41,519,399 Methylomic Proﬁling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
cg16140558 1.85E-08 8 41,514,039 Methylomic Proﬁling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
ASGR2 cg18659586 1.06E-09 GO:0,004,873 asialoglycoprotein
receptor activity
GO:0,005,515 protein binding
GO:0,030,246 carbohydrate
binding
17 7,017,474 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
ATG16L2 cg21806242 3.71E-10 Regulation of autophagy 11 72,532,891 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
BCAR3 cg02342148 1.60E-08 GO:0,005,085 guanyl-nucleotide
exchange factor activity
GO:0,005,515 protein binding
1 94,145,223 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
BIN1 cg22883290 3.73E-08 GO:0,005,515 protein binding
GO:0,032,403 protein complex
binding
GO:0,042,802 identical protein
binding
GO:0,046,982 protein
heterodimerization activity
GO:0,048,156 tau protein binding
2 127,800,646 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
CDA cg26407544 2.10E-10 GO:0,001,882 nucleoside binding
GO:0,004,126 cytidine deaminase
activity
GO:0,005,515 protein binding
GO:0,008,270 zinc ion binding
1 20,945,355 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
CDH23,
C10orf54
cg23968456 1.09E-08 GO:0,005,509 calcium ion binding
GO:0,005,515 protein binding
10 73,521,631 Methylomic Proﬁling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al.,
2014)
3.97E-10 10 73,521,631 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
CXXC5 cg07354506 9.26E-08 GO:0,004,871 signal transducer
activity
GO:0,005,515 protein binding
GO:0,008,134 transcription factor
binding GO:0,008,270 zinc ion
binding
5 139,048,148 Methylomic Proﬁling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
FOXK1 cg07180538 4.95E-08 GO:0,000,977 RNA polymerase II
regulatory region
7 4,786,899 Alzheimer's Disease: Early
Alterations in Brain DNA
De Jager,
2014
(De Jager et al., 2014)
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Table 2 (continued)
Gene Probes
identiﬁed
P value Functional summary, GO
annotation
Chromosome Position Title of article First author
and year
Reference
sequence-speciﬁc DNA binding
GO:0,000,981 sequence-speciﬁc
DNA binding RNA polymerase II
transcription factor activity
GO:0,005,515 protein binding
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
cg25594100 2.54E-11 7 4,786,943 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
GMDS cg07714812 3.81E-08 GO:0,005,515 protein binding
GO:0,008,446 GDP-mannose
4,6-dehydratase activity
GO:0,070,401 NADP+ binding
6 1,635,611 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
GUCY2D cg04157161 7.80E-08 GO:0,004,383 guanylate cyclase
activity
GO:0,004,672 protein kinase
activity
GO:0,004,872 receptor activity
GO:0,005,524 ATP binding
17 7,906,847 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
HMHA1 cg02308560 3.06E-08 GO:0,005,096 GTPase activator
activity
GO:0,005,515 protein binding
GO:0,046,872 metal ion binding
19 1,071,176 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
ITM2C cg18346707 3.30E-08 GO:0,001,540 beta-amyloid
binding
GO:0,005,515 protein binding
GO:0,005,524 ATP binding
2 231,732,249 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
ITPRIPL2 cg16733298 5.24E-08 membrane-associated protein,
intracellular calcium signaling
16 19,127,132 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
KCNN4 cg22904711 1.08E-08 GO:0,005,515 protein binding
GO:0,005,516 calmodulin binding
GO:0,015,269 calcium-activated
potassium channel activity
GO:0,016,286 NOT small
conductance calcium-activated
potassium channel activity
19 44,278,628 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
KDM2B cg11724984 4.76E-09 GO:0,003,677 DNA binding
GO:0,005,515 protein binding
GO:0,008,270 zinc ion binding
GO:0,019,843 rRNA binding
GO:0,032,452 histone
demethylase activity
12 121,890,864 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
LNX1 cg12114584 5.81E-13 GO:0,004,842 ubiquitin-protein
transferase activity
GO:0,005,515 protein binding
GO:0,008,270 zinc ion binding
GO:0,016,874 ligase activity
GO:0,030,165 PDZ domain
binding
4 54,518,744 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
LYVE1 cg18343862 4.96E-08 GO:0,004,872 receptor activity
GO:0,004,888 transmembrane
signaling receptor activity
GO:0,005,515 protein binding
GO:0,005,540 hyaluronic acid
binding
11 10,590,003 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
MAFB cg13579486 3.25E-08 GO:0,003,700 sequence-speciﬁc
DNA binding transcription factor
activity
GO:0,005,515 protein binding
GO:0,008,134 transcription factor
binding
GO:0,043,565 sequence-speciﬁc
DNA binding
20 39,314,091 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al.,
2014)
MCF2L cg07883124 6.31E-12 GO:0,005,089 Rho
guanyl-nucleotide exchange
factor activity
GO:0,005,545
1-phosphatidylinositol binding
13 113,634,042 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
cg09448088 6.43E-10 13 113,635,690 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
MYO10 cg06742628 1.58E-10 GO:0,005,515 protein binding
GO:0,005,516 calmodulin binding
5 16,886,424 Alzheimer's Disease: Early
Alterations in Brain DNA
De Jager,
2014
(De Jager et al., 2014)
(continued on next page)
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Table 2 (continued)
Gene Probes
identiﬁed
P value Functional summary, GO
annotation
Chromosome Position Title of article First author
and year
Reference
GO:0,005,524 ATP binding
GO:0,005,547
phosphatidylinositol-
3,4,5-trisphosphate binding
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
MYO1C cg05417607 2.25E-08 GO:0,003,774 motor activity
GO:0,003,779 actin binding
GO:0,005,102 receptor binding
GO:0,005,515 protein binding
GO:0,005,516 calmodulin binding
17 1,373,605 Methylomic Proﬁling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
2.52E-08 17 1,373,605 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
PASK cg25488284 3.50E-08 GO:0,004,674 protein serine/
threonine kinase activity
GO:0,004,871 signal transducer
activity
GO:0,005,515 protein binding
2 242,048,127 Methylomic Proﬁling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
PCNT cg00621289 6.48E-08 GO:0,005,515 protein binding
GO:0,005,516 calmodulin binding
21 47,855,916 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
cg04147621 1.39E-08 21 47,856,020 Methylomic Proﬁling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
cg23449541 9.39E-08 21 47,855,893 Methylomic Proﬁling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
PLAT cg17693222 2.14E-08 GO:0,004,252 serine-type
endopeptidase activity
GO:0,005,515 protein binding
8 42,033,472 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
PLXNC1 cg12877335 2.36E-11 GO:0,004,872 receptor activity
GO:0,005,102 receptor binding
GO:0,005,515 protein binding
12 94,539,319 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
PODXL cg08737189 3.37E-08 GO:0,005,515 protein binding 7 131,223,417 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
cg19140834 1.22E-09 7 131,217,668 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
PSMA1 cg27443779 1.18E-08 GO:0,003,723 RNA binding
GO:0,004,298 threonine-type
endopeptidase activity
GO:0,005,515 protein binding
11 14,664,793 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
PSTPIP1 cg11652496 2.57E-09 GO:0,003,779 actin binding
GO:0,005,515 protein binding
GO:0,019,903 protein
phosphatase binding
15 77,324,526 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
RBM33 cg13639901 1.54E-13 GO:0,000,166 nucleotide binding
GO:0,044,822 poly(A) RNA
binding
7 155,556,590 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
cg14430943 2.71E-10 7 155,556,652 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
RHBDF2 cg05810363 9.42E-10 GO:0,004,252 serine-type
endopeptidase activity
GO:0,019,838 growth factor
binding
17 74,475,270 Methylomic Proﬁling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
3.68E-10 17 74,475,270 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
cg12163800 2.66E-08 17 74,475,355 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
cg13076843 3.81E-08 17 74,475,294 Methylomic Proﬁling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon,
2014
(Lunnon et al., 2014)
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Table 2 (continued)
Gene Probes
identiﬁed
P value Functional summary, GO
annotation
Chromosome Position Title of article First author
and year
Reference
1.68E-09 17 74,475,294 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
SH3PXD2A cg19007269 2.96E-09 GO:0,005,515 protein binding
GO:0,035,091
phosphatidylinositol binding
10 105,420,501 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
SIX3 cg22385702 4.47E-10 GO:0,000,980 RNA polymerase II
distal enhancer sequence-speciﬁc
DNA binding
GO:0,001,205 RNA polymerase II
distal enhancer sequence-speciﬁc
DNA binding transcription factor
activity involved in positive
regulation of transcription
GO:0,001,222 transcription
corepressor binding
GO:0,003,700 sequence-speciﬁc
DNA binding transcription factor
activity
2 45,175,881 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
SLC15A4 cg06653632 9.77E-08 GO:0,005,290 L-histidine
transmembrane transporter
activity
GO:0,015,293 symporter activity
12 129,281,444 Methylomic Proﬁling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon K (Lunnon et al., 2014)
SLC16A3 cg07012687 6.19E-09 GO:0,005,515 protein binding
GO:0,008,028 monocarboxylic
acid transmembrane transporter
activity
GO:0,015,129 lactate
transmembrane transporter
activity
GO:0,015,293 symporter activity
GO:0,015,355 secondary active
monocarboxylate transmembrane
transporter activity
17 80,195,180 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
SPG7 cg03169557 7.95E-09 GO:0,004,222
metalloendopeptidase activity
GO:0,005,515 protein binding
GO:0,005,524 ATP binding
GO:0,008,233 peptidase activity
GO:0,008,270 zinc ion binding
16 89,598,950 Methylomic Proﬁling Implicates
Cortical Deregulation of ANK1 in
Alzheimer's Disease
Lunnon K (Lunnon et al., 2014)
3.99E-10 16 89,598,950 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
STK32C cg25917732 9.98E-08 GO:0,004,672 protein kinase
activity
GO:0,004,674 protein serine/
threonine kinase activity
GO:0,004,713 protein tyrosine
kinase activity null
GO:0,005,524 ATP binding
GO:0,016,772 transferase activity,
transferring
phosphorus-containing groups
10 134,038,395 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
TFAP2E cg17474422 1.56E-08 GO:0,000,977 RNA polymerase II
regulatory region
sequence-speciﬁc DNA binding
GO:0,000,981 sequence-speciﬁc
DNA binding RNA polymerase II
transcription factor activity
GO:0,042,803 protein
homodimerization activity
1 36,039,866 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
TMEM18 cg21644387 7.25E-08 GO:0,003,677 DNA binding 2 663,024 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
TPRG1 cg04252044 2.42E-10 GO:0,042,802 identical protein
binding
3 188,664,747 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
cg12307200 3.06E-17 3 188,664,632 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
(continued on next page)
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TTC22 cg15645660 4.05E-08 Chaperone activity 1 55,247,356 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
VRTN cg21207436 2.24E-09 GO:0,004,803 transposase activity
GO:0,043,565 sequence-speciﬁc
DNA binding
14 74,815,316 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
VWF cg27041424 4.47E-10 GO:0,001,948 glycoprotein
binding
GO:0,002,020 protease binding
GO:0,005,178 integrin binding
GO:0,005,515 protein binding
GO:0,005,518 collagen binding
12 6,232,979 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
WDR81 cg19803550 1.04E-08 GO:0,016,772 transferase activity,
transferring
phosphorus-containing groups
17 1,637,391 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
ZZEF1 cg06753513 3.87E-12 GO:0,005,509 calcium ion binding
GO:0,008,270 zinc ion binding
17 3,977,385 Alzheimer's Disease: Early
Alterations in Brain DNA
Methylation at ANK1, BIN1,
RHBDF2 and Other Loci
De Jager,
2014
(De Jager et al., 2014)
Shown are the genes identiﬁed from EWAS and their respective probes, associated P value, GO annotation, chromosome and genomic position, and the relevant study. Only probes
with Pb 1 × 10−7 were included.
44 A.R. Smith et al. / Neuroepigenetics 6 (2016) 32–50study designs, we identiﬁed 5 common pathways altered at the
genetic and/or epigenetic level in AD: plasma membrane and
cytoskeletal processes, lipid homeostasis, synaptic signaling, immune
cell processes, and mitochondrial processes (Fig. 2). The largest
number of genes fell into the functional group plasma membrane and
cytoskeletal processes (n = 14); however, this could be due to the
fact that this is a proportionally larger pathway and is therefore more
likely to contain an associated gene by chance. Of the pathways weFig. 2. Cellular pathways of genes identiﬁed from GWAS or EWAS. The 32 most signiﬁcant G
(red) were identiﬁed from De Jager et al. (2014) and Lunnon et al. (2014) (Table 2). The 4 gr
al. (2012), (2013), and Pottier et al. (2012) (Table 1B). We next compared the molecular and
between studies.have identiﬁed, many of them have considerable overlap; for
example, lipid processes are intrinsically linked to the plasma
membrane which is composed of phospholipids and a large
percentage of cholesterol. To better understand the overlap between
GWAS and EWAS nominated genes, we looked at the cellular
localization of genes from each type of study (Fig. 3). The 2 largest
localization groups (cellular membrane and nucleus) were consistent
between methodologies. This would, to some degree, be expectedWAS loci identiﬁed (Table 1A) are shown in black. The 48 most signiﬁcant EWAS loci
een loci were identiﬁed via exome sequencing from Cruchaga et al. (2014), Guerreiro et
cellular pathways of the proteins encoded by these genes to look for functional overlap
Fig. 3. Cellular locations of genes nominated from (A) GWAS and (B) EWAS.
45A.R. Smith et al. / Neuroepigenetics 6 (2016) 32–50because the majority of total proteins are involved in these locations
and, in addition, current protein research has focused on these areas
of the cell.
To provide a more structured approach to pathway analysis, all 81
genes were entered into the PANTHER pathway analysis using the
enrichment analysis from gene ontology consortium (Mi et al., 2013).
Fourteen biological process and 4 cellular component pathways were
identiﬁed after passing Bonferroni correction. Most pathways
reﬂected an interaction with Aβ or other AD pathology (Fig. 4). As
the data for these genes were most likely collected from ADFig. 4. Pathway enrichment analysis of 81 identiﬁedgenes. (A) ThePanther GO tool identiﬁed14
(B) Cellular component pathways identiﬁed by the Panther GO tool identiﬁed 4 cellular compo
columns represent expected number of genes in each pathway, whereas red represents the acpublications, the resulting pathways are not unexpected but are
most likely to be limited.
3.1. Plasma membrane/cytoskeleton
This is the pathway which contained the largest number of
associated genes from our analysis (n = 14). The plasma membrane
insulates the intracellular components from the extracellular envi-
ronment, as well as catalyzing the transport of speciﬁc compounds,
including nutrients and ions. Phospholipids that make up thesigniﬁcantly enrichedbiological processes pathways (P b .05) after Bonferroni correction.
nent pathways that were signiﬁcantly enriched (P b .05) after Bonferroni correction. Blue
tual number of genes identiﬁed. Key: * = Pb0.05, ** = Pb0.01, *** = Pb0.005.
46 A.R. Smith et al. / Neuroepigenetics 6 (2016) 32–50membrane provide suitable ﬂuidity and permeability. Alterations in
the receptor function, membrane integrity, and membrane-
dependent processes seen in AD have been reviewed by A. Farooqui
et al. (Farooqui et al., 1995). The cytoskeleton provides contractility
and couples biochemical responses with mechanical stresses in cells.
It is vital in themovement of cellular machinery around the cell and to
the membrane, as well as orchestrating the procedures needed for
cellular movement and reshaping, a function speciﬁcally important to
the microglial cells of the brain in the response to inﬂammation
(Sheng et al., 1997). For an overview of cell mechanics and the
cytoskeleton, see the review by Fletcher and Mullins 2010 (Fletcher &
Mullins, 2010). The inability of neurons to regulate calcium
homeostasis through cell surface ion channels is an aspect of AD
pathogenesis that appears to be intimately involved in the dysfunc-
tion and death of neurons (Mattson, 2004). Familial AD mutations in
APP and PSEN1 support a role for perturbed calcium regulation in AD
(Mattson, 2004). In addition, all of the enzymatic machinery
responsible for the generation of the pathogenic Aβ plaque formation
are plasma membrane based (Lukiw, 2013), suggesting that damage
to the plasma membrane may be a key factor in the Aβ pathology
typical of AD.
BIN1 has been nominated by both GWAS and EWAS, and in
addition to its role in synaptic signaling, it also has a role in plasma
membrane/cytoskeletal processes because it acts as an amphiphysin,
which is known to promote caspase-independent apoptosis as well as
play an important role in neuronal membrane organization (Wigge
et al., 1997). Major learning defects and seizures have been linked to
decreased expression of amphiphysins inmurine brain (Di Paolo et al.,
2002). In addition, altered expression of BIN1 has been shown in aging
mouse models of AD (Yang et al., 2008), providing further evidence
for its role in AD pathology. Despite having no previous link to AD,
ANK1 is now the one of the strongest reported candidate genes in AD
EWAS, with strong links to cell structure. ANK1 was found to be
hypermethylated in AD brain in 2 separate studies, including 1 with 2
independent validation cohorts (Lunnon et al., 2014; De Jager et al.,
2014). The differentially methylated region in this gene spans at least
6 CpG sites and was signiﬁcantly associated with neuropathology in
cortical regions but not cerebellum or premortem blood (Lunnon
et al., 2014), indicating tissue speciﬁcity of the differentially
methylated region to regions of neuropathology. ANK1 is found in
multiple different isoforms, with some transcript variants speciﬁc to
the brain (Gallagher et al., 1997) and some evidence for differential
splicing in AD (Lunnon et al., 2014). As with BIN1, one of the main
functions of ANK1 is compartmentalization and maintenance of the
plasmamembrane, and it is possible that the altered expression of this
gene could lead to neuronal membrane dysfunction in AD (Lunnon
et al., 2014).
The PVRL2 gene identiﬁed by GWAS encodes a single-pass type I
membrane glycoprotein, which is one of the plasma membrane
components of adherens junctions. Cell to cell connections brought
about by adherens junctions are vital for effective neuronal signaling
(Marambaud et al., 2002). Interestingly, Marambaud et al. used
various immunological-based methods to investigate the PSEN1/
γ-secretase system, where mutations are associated with familial AD,
and showed that it disrupted adherens junctions in AD (Marambaud
et al., 2002). Expression of PVRL2 has been detected in many
organs including the brain, and it was later suggested that it was
associated with human longevity along with the AD GWAS
nominated loci TOMM40 and APOE (Lu et al., 2014). In addition,
Elias-Sonnenschein et al. showed a signiﬁcant correlation between
the GWAS nominated locus MS4A4A and Aβ but not tau pathology in
AD (Elias-Sonnenschein et al., 2013). Despite this, there is little to no
research on the speciﬁc function of MS4A4A, although the gene
product is associated with GO pathways that indicate that it is an
integral component of the plasmamembrane. Two other genes within
the MS4A gene cluster have also been nominated via GWAS: MS4A4Eand MS4A6A (Hollingworth et al., 2011; Lambert et al., 2013a). One
recent study demonstrated that MS4A6A genotype and AD are
associated with differential expression of isoform variants in blood
and some brain regions (Proitsi et al., 2014).
3.2. Lipid homeostasis
Recent epidemiological, molecular, and biochemical evidence has
strengthened the hypothesis that cholesterol is a risk factor for AD, and
although cholesterol homeostasis in the brain is largely unexplored,
new ﬁndings strongly support the involvement of cholesterol in both
the generation and deposition of Aβ (Puglielli et al., 2003). Speciﬁcally,
the quantity of cholesterol in the neuronal plasmamembrane has been
shown tomakeneuronsmore susceptible to thedamage causedbyAβ in
AD (Arispe & Doh, 2002). Other studies suggest that cholesterol acts
directly on the amyloid cascadebypromotingamyloidogenic processing
of APP (Mattson, 2004). Interestingly, statins, which are a class of
cholesterol-lowering drugs, decrease Aβ levels as well as plaque
deposition in APP transgenic mouse models (Fassbender et al., 2001).
In addition, high cholesterol levels and changes to cholesterol
metabolism can increase the production of Aβ in cell culture and
murine models (Puglielli et al., 2003). Three of the most signiﬁcant
genes from AD GWAS are associated with lipid metabolism (APOE,
APOC1, CLU). APOE was ﬁrst identiﬁed as a risk factor for AD in 1993
(Strittmatter et al., 1993) using immunostaining and genotyping
analysis of 30 AD cases and 91 controls. Since 2006 and the wide
application of GWAS to AD research (Grupe et al., 2007), the APOE
polymorphism has been successfully replicated in several other studies
(Coon et al., 2007; Abrahamet al., 2008; Kramer et al., 2011; Logue et al.,
2011; Meda et al., 2012; Ramanan et al., 2014), making APOE the most
robust gene linked to late-onset AD (LOAD) risk to date. The proportion
of genetic variance for LOAD risk attributed to APOE genotype is
estimated to be10%–20% (Slooter et al., 1998).APOE is a 299–amino acid
glycoprotein and the major protein component of very low density
lipoproteins, the major apolipoprotein in the brain (Puglielli et al.,
2003), as well as having a functional role in cholesterol and triglyceride
metabolism (Breslow et al., 1982). There are 3 APOE alleles that affect
one's risk of AD (ε2, ε3, and ε4), in addition to age of onset (Roses &
Allen, 1996). Of the 3 alleles, APOE ε2 demonstrates a protective effect,
with an odds ratio of 0.3 for possessing one ε2 allele, whereas APOE ε4 is
associated with a higher LOAD risk, with an odds ratio of 4.4 and 19.3,
respectively for having 1 or 2 alleles (Corder et al., 1994), as well as a
younger median age of dementia onset (Corder et al., 1994; Reiman
et al., 2007). It has been suggested that the mutated APOE hinders
clearanceof solubleAβprotein fromthebrain, leading toAβ aggregation
into ﬁbrils. Furthermore, APOE has been shown to promote neurode-
generation by directing the toxic Aβ oligomers to synapses (Ramanan
et al., 2014). However, a recent positron emission tomographic study to
measure Aβ in 602 individuals found that the ε4 allele is neither
necessary nor sufﬁcient for thedevelopmentof ADpathology (Ramanan
et al., 2014).
SORL1 has been identiﬁed in several studies of AD using GWAS and
exome sequencing methods; in addition, Yu et al. found epigenetic
changes in this gene (Yu et al., 2014). It has many functional domains
with different functions, including cargo transport, chaperone-like
activity, signaling, and intracellular sorting (Jacobsen et al., 2001).
When acting as a sorting receptor, the SORL1 gene product protects
APP from being directed to the endosome where it would be cleaved
by β-secretase, producing Aβ (Louwersheimer et al., 2015). Further-
more, SORL1 can bind APOE, making SORL1 an important component
in the pathophysiology of AD (Elias-Sonnenschein et al., 2013).
3.3. Synaptic signaling
Synaptic dysfunction is possibly the best established of all the
proposed pathological mechanisms for AD to date, as it shows clear
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changes (Masliah et al., 2001). Early stages of AD are characterized by
a 25%–35% decrease in numerical density of synapse per cortical
region (Davies et al., 1987). There has also been evidence that the loss
of synapses correlates with the soluble pool of cortical Aβ (Lue et al.,
1999). Stereological and biochemical analyses have shown that the
reduction in synaptic density within AD brain correlates with
cognitive defects better than the traditional hallmarks of Aβ plaques
and neuroﬁbrillary tangles (Masliah et al., 2001).
We have identiﬁed 4 genes from GWAS and EWAS analyses of AD
that have been linked to synaptic function. Two of these, BIN1 and
PICALM, have functions in vesicular trafﬁcking. Speciﬁcally, studies
have shown that the BIN1 gene has roles in a number of speciﬁc
pathways, including clathrin-mediated endocytosis which is an
essential step in the intracellular trafﬁcking of proteins and lipids
such as nutrients, growth factors, and neurotransmitters in synapses
(Cousin & Robinson, 2001; Dreyling et al., 1996; Wigge & McMahon,
1998). Originally identiﬁed as a tumor suppressor (Sakamuro et al.,
1996), the BIN1 gene product is expressed most abundantly in brain
and muscle (Wechsler-Reya et al., 1997), with several alternatively
spliced brain-speciﬁc isoforms. BIN1 is one of the few genes
reproducibly identiﬁed by GWAS that does not fall near or within
the APOE locus; in addition, it is the only gene in our analysis to be
signiﬁcantly associated with AD in both GWAS and EWAS.
Like BIN1, PICALM is also involved in clathrin-mediated endocy-
tosis (Dreyling et al., 1996). PICALM directs the trafﬁcking of the
VAMP2 protein. VAMP2 is a SNARE protein that plays a key role in the
fusion of vesicles to the presynaptic membrane, allowing neurotrans-
mitter release into the synapse, a process essential to neuronal
function (Harel et al., 2008). PICALM has been robustly identiﬁed as a
risk factor for AD via GWAS (Harold et al., 2009; Seshadri et al., 2010);
however, AD-linked SNPs identiﬁed in PICALMmay still be affected by
APOE genotype because of the large amount of attenuation seen when
adjusted for APOE status (Hu et al., 2011). Jun et al. have also reported
this interaction observing that genotypes of PICALM conferred risk
predominantly in APOE ε4–positive participants, providing strong
evidence for a synergistic effect (Jun et al., 2010). PICALM is also
thought to affect amyloid precursor protein processing via endocytic
pathways (Harold et al., 2009).
As a previously known risk factor gene forAD(Lambert et al., 2013a),
PTK2B was shown via network analyses to be linked to RHBDF2, ANK1,
and RPL13, which were recently nominated from EWAS, providing
further evidence for a role in AD pathology (De Jager et al., 2014). PTK2B
has a number of roles including the induction of long-term potentiation
of nerve cells, a central process of memory formation; cell migration;
and synaptic function (Lambert et al., 2013a).
3.4. Immune cell dysfunction (astrocytes, oligodendrocytes, and microglia)
There is a widely accepted link between inﬂammation, the
immune system, and AD pathology (Adriana Martorana et al., 2012;
Akiyama et al., 2000;Monson et al., 2014; Salminen et al., 2009; Tuppo
& Arias, 2005); more speciﬁcally, the inﬂammation seen in AD has
been proposed to exacerbate symptoms (Akiyama et al., 2000).
Microglia, which are the brain's resident macrophages, have been
shown to increase their viability by 22.0%–29.4% in response to
ﬁbrillar Aβ deposits of 0.2 to 5.0 μmol/L, which are commonly seen in
AD. Oligomeric Aβ at a dose of 5.0 μmol/L results in cytotoxic
microglia (Pan et al., 2011) and ultimately leads to synaptic
degeneration and neuronal death (Barger & Basile, 2001). However,
relatively few genes that have shown robust associations with AD
have been directly linked with inﬂammation or immune functions.
Most noteworthy, a rare variant in TREM2was recently recognized by
a number of AD exome sequencing studies and GWAS (Guerreiro et
al., 2013; Jonsson et al., 2013; Forabosco et al., 2013; Neumann & Daly,
2012). TREM2 encodes an innate immune system receptor on thesurface of microglial cells within the brain. With the signaling
counterpart DAP12 (also called TYROBP), TREM2 forms a molecular
complex that promotes phagocytosis of bacteria (N'Diaye et al., 2009).
Work by Takahashi et al. has shown that TREM2 also has a role in the
clearance of apoptotic neurones due to its ability to increasemigration
and phagocytosis of microglia (Takahashi et al., 2005). Recently, 1
study demonstrated correlation in TREM2 and CD33 gene expression
in AD (Chan et al., 2015). As CD33 has also been nominated in various
AD GWAS (Hollingworth et al., 2011; Naj et al., 2011; Kamboh et al.,
2012b), this provides further evidence for an overlap of AD gene
pathways in disease. As described above, recent protein-protein
interaction data also demonstrated that several EWAS nominated loci
(ANK1, RHBDF2, PICLAM) have a functional link to PTK2B (De Jager
et al., 2014). PTK2B is an AD risk factor gene that plays a key role in the
signaling cascade involved in the modulation of microglial and
inﬁltrating macrophage cell activation (De Jager et al., 2014).
A further gene related to immune function is RHBDF2, identiﬁed by
EWAS. Differentially methylated CpG sites close to the RHBDF2 gene
were identiﬁed in 2 independent EWAS (Lunnon et al., 2014; De Jager
et al., 2014), with recent studies showing that this increases RHBDF2
expression in AD brain (De Jager et al., 2014). RHBDF2 transports
TNFα converting enzyme (TACE, also called ADAM17), which is
necessary for the release of TNFα from the cell surface (Adrain et al.,
2012). RHBDF2 absence in mice affects the release of TNFα from the
cell surface (Siggs et al., 2012) and therefore impairs systemic
immune responses to pathogens (McIlwain et al., 2012), although
the brain phenotype has yet to be researched.3.5. Mitochondrial processes
Mitochondrial dysfunction is one of the most prominent charac-
teristics of AD in both the brain and the periphery (Devall et al., 2016;
Devall et al., 2014; Lunnon et al., 2012), with TOMM40, one of themost
robust genes identiﬁed from GWAS, associated with mitochondrial
function. This gene is located approximately 2 kilobases downstream
from APOE, and because of the locality of these 2 genes, there is strong
linkage disequilibrium (LD) for TOMM40with the APOE locus (Feulner
et al., 2010); hence, many studies have failed to ﬁnd an association of
TOMM40 in AD after adjusting for APOE genotype (Ramanan et al.,
2014; Wijsman et al., 2011; Yu et al., 2007). However, 1 study reports
TOMM40 as a possible risk factor of AD independent of APOE (Lutz et
al., 2010). Speciﬁcally, this study found a poly-T track mutation in
TOMM40 that acts independently of APOE genotype, which has also
seen been reported in another independent study (Cruchaga et al.,
2011). In addition to increasing risk of developing AD, TOMM40 has
also been linked to an earlier age of onset for the disease (Roses et al.,
2009). Other studies also suggest that TOMM40 provides an additional
risk for AD, in addition to APOE (Potkin et al., 2009; Takei et al., 2009).
However, until the extent of the LD between TOMM40 and APOE is
fully characterized, it will be difﬁcult to pinpoint the exact effect the
TOMM40 mutation has on LOAD pathogenesis.
CLU has various nuclear andmitochondrial isoforms and is thought
to regulate the rate of cell proliferation. CLU has been consistently
replicated across many GWAS and holds a strong association with AD
(Harold et al., 2009; Lambert et al., 2009; Jun et al., 2010; Wijsman et
al., 2011). The nuclear isoforms result in the promotion of apoptosis,
whereas mitochondrial isoforms of CLU suppress BAX-dependent
release of cytochrome c into the cytoplasm and inhibit apoptosis
(Zhang et al., 2005). As an increased level of apoptosis in the brain is
seen in AD, it could suggest a role of CLU mutations in pathogenesis
(Behl, 2000). SPG7 was identiﬁed by EWAS and encodes a mitochon-
drial metalloprotease protein. Mitochondrial proteases degrade
misfolded and nonassembled polypeptides. They also regulate the
activity of speciﬁc substrates by mediating essential processing steps.
These proteases have been hypothesized to play a role in
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axonal function (Martinelli & Rugarli, 2010).4. Discussion
The use of GWAS to identify common disease variants in AD has
been at the forefront of research to understanding disease etiology for
10 years. More recently, the falling cost of exome and whole genome
sequencing has identiﬁed rarer variants with a larger effect size.
However, only 3 EWAS have been reported in AD to date (Lunnon et
al., 2014; De Jager et al., 2014; Bakulski et al., 2012), which have solely
focused on DNA methylation, although further studies are highly
anticipated. Of all the genes identiﬁed from GWAS and EWAS in AD,
only 1 locus was found to be overlapping between these 2
methodologies (BIN1).
As with any pathway identiﬁcation analysis, there are caveats to
our method. Some pathways are signiﬁcantly larger than others
containing more genes; therefore, using this method, we are more
likely to ﬁnd associated genes in these pathways over others.
Secondly, cellular pathways that contain a gene which is either
genetically or epigenetically altered may still be able to function
normally, as similar proteins could “step-in” to fulﬁll the lost
functionality. Thirdly, in our analysis, we did not ﬁlter our results
based on loss of function SNPs or reduced expression; therefore,
despite the alterations in AD, the genes we have identiﬁed may well
have no change in their functionality. Fourthly, AD is characterized by
neuronal cell loss and gliosis, and thus, the ﬁndings from EWAS may
simply represent an alteration in cellular abundance, and although
EWAS can apply cell-speciﬁc corrections to methylation data
(Guintivano et al., 2013), this was not included in our analysis. The
ability to look at single-cell epigenetic proﬁles in disease would allow
researchers to conclusively quantify changes that occur at both
cellular and disease-state levels; however, single-cell isolation in
postmortem tissue, via laser capture microdissection or
ﬂorescent-assisted cell sorting, currently represents a considerable
challenge to the ﬁeld. Finally, epigenetic research in AD is still in its
early stages with only 2 EWAS included in our analysis; this coupled
with the fact that current methylation data are the sum of 2 different
cytosine modiﬁcations (5-methylcytosine and 5-hmC) means that we
may have an underrepresentation of signiﬁcant EWAS genes in AD. A
further caveat of epigenetic studies compared with genetic studies is
that causality is more difﬁcult to establish, and thus, further studies
examining the functional role of nominated EWAS loci are warranted.5. Conclusion
Looking at the most signiﬁcant genetic and epigenetic ﬁndings in
AD to date, we have identiﬁed several pathways that require further
exploration and could ultimately aid in our understanding of AD
etiology. Well-characterized clinical cohorts will also allow the
identiﬁcation of further rare variants of AD, whereas advances in
methodologies are also allowing the identiﬁcation of other epigenetic
marks, such as histone modiﬁcations and other DNA modiﬁcations at
single-nucleotide resolution (Lunnon & Mill, 2013). A number of
recent studies have demonstrated altered global levels of 5-hmC in AD
brain (Condliffe et al., 2014; Chouliaras et al., 2013); however,
studies to investigate loci-speciﬁc 5-hmC changes in AD are yet to be
published. There is also the potential for further disease mechanisms
to be identiﬁed from current studies as research moves to integrate
GWAS and EWAS data in the same data sets to identify cis
methylation quantitative trait loci. Ultimately, integrating genomic
and epigenomic data with other “omic” modalities will allow the
identiﬁcation of novel dysfunctional pathways in disease (Lunnon &
Mill, 2013).Acknowledgements
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